Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients

被引:16
|
作者
Fernandez-Diaz, Carlos [1 ]
Atienza-Mateo, Belen [1 ]
Castaneda, Santos [2 ]
Melero-Gonzalez, Rafael B. [3 ]
Ortiz-SanJuan, Francisco [4 ]
Loricera, Javier [1 ]
Casafont-Sole, Ivette [5 ]
Rodriguez-Garcia, Sebastian [6 ]
Aguilera-Cros, Clara [7 ]
Villa-Blanco, Ignacio [8 ]
Raya-Alvarez, Enrique [9 ]
Ojeda-Garcia, Clara [10 ]
Bonilla, Gema [11 ]
Lopez-Robles, Alejandra [12 ]
Arboleya, Luis [13 ]
Narvaez, Javier [14 ]
Cervantes, Evelin [15 ]
Maiz, Olga [16 ]
Alvarez-Rivas, Maria N. [17 ]
Cabezas, Ivan [18 ]
Salgado, Eva [19 ]
Hidalgo-Calleja, Cristina [20 ]
Fernandez, Sabela [21 ]
Fernandez, Jesus C. [22 ]
Ferraz-Amaro, Ivan [23 ]
Gonzalez-Gay, Miguel A. [1 ]
Blanco, Ricardo [1 ]
机构
[1] Univ Cantabria, Rheumatol, HU Marques de Valdecilla, IDIVAL, Santander, Spain
[2] UAM, Rheumatol, HU La Princesa, IIS Princesa,Catedra UAM Roche EPID Future, Madrid, Spain
[3] CHU Vigo, Rheumatol, Vigo, Spain
[4] HU La Fe, Rheumatol, Valencia, Spain
[5] HU Germans Trias & Pujol, Rheumatol, Madrid, Spain
[6] HU Clin, Rheumatol, Barcelona, Spain
[7] HU Virgen del Rocio, Rheumatol, Seville, Spain
[8] H Torrelavega, Rheumatol, Cantabria, Spain
[9] HU San Cecilio, Rheumatol, Granada, Spain
[10] HU Virgen Macarena, Rheumatol, Seville, Spain
[11] HU La Paz, Rheumatol, Madrid, Spain
[12] HU Leon, Rheumatol, Leon, Spain
[13] HU Cent Asturias, Rheumatol, Asturias, Spain
[14] HU Bellvitge, Rheumatol, Barcelona, Spain
[15] HU Santiago, Rheumatol, Santiago De Compostela, A Coruna, Spain
[16] HU Donostia, Rheumatol, Donosti, Spain
[17] HU Luca Augusti, Rheumatol, Lugo, Spain
[18] HU Rio Hortega, Rheumatol, Valladolid, Spain
[19] CHU Ourense, Rheumatol, Orense, Spain
[20] HU Salamanca, Rheumatol, Salamanca, Spain
[21] HU Cabuenes, Rheumatol, Asturias, Spain
[22] CHU A Coruna, Rheumatol, La Coruna, Spain
[23] HU Canarias, Rheumatol, Tenerife, Spain
关键词
rheumatoid arthritis; interstitial lung disease; abatacept; methotrexate; conventional disease-modifying antirheumatic drugs; high-resolution computed tomography; comorbidity; METHOTREXATE; MORTALITY; CLASSIFICATION; PNEUMONITIS; CRITERIA; RISK; DRUG;
D O I
10.1093/rheumatology/keab317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABA(MONO)) vs combined ABA [ABA plus MTX (ABA(MTX)) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABA(NON-MTX))] in RA patients with interstitial lung disease (ILD) (RA-ILD). Methods This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABA(MONO), ABA(MTX), ABA(NON-MTX)) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups. Results We studied 263 RA-ILD patients (mean +/- s.d. age 64.6 +/- 10 years) [ABA(MONO) (n = 111), ABA(MTX) (n = 46) and ABA(NON-MTX) (n = 106)]. At baseline, ABA(MONO) patients were older (67 +/- 10 years) and took higher prednisone dose [10 (interquartile range 5-15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABA(MTX) or ABA(NON-MTX)). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups. Conclusion In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA.
引用
收藏
页码:299 / 308
页数:10
相关论文
共 50 条
  • [21] INTERSTITIAL LUNG DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS OF A COHORT TREATED WITH METHOTREXATE MONOTHERAPY
    Chamizo-Carmona, E.
    Carrasco Cubero, C.
    Rojas Herrera, S. M.
    Malave Calzada, J.
    Veroz Gonzalez, R.
    Chaves Chaparro, L. M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 576 - 576
  • [22] REFRACTORY RHEUMATOID ARTHRITIS WITH INTERSTITIAL LUNG DISEASE: COULD ABATACEPT BE THE ANSWER?
    Hayes, Fiona
    Oestoer, Andrew
    RHEUMATOLOGY, 2014, 53 : 65 - 65
  • [23] SAFETY OF ABATACEPT IN RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASE (APRIL)
    Gudu, Tania
    Stober, Carmel
    Fifield, Maeve
    Babar, Judith
    Ostor, Andrew
    Parfrey, Helen
    Hall, Francess
    RHEUMATOLOGY, 2021, 60
  • [24] Fibrosing Progressive Interstitial Lung Disease in Rheumatoid Arthritis: A Multicentre Italian Study
    Sebastiani, Marco
    Venerito, Vincenzo
    Laurino, Elenia
    Gentileschi, Stefano
    Atzeni, Fabiola
    Canofari, Claudia
    Andrisani, Dario
    Cassone, Giulia
    Lavista, Marlea
    D'Alessandro, Francesco
    Vacchi, Caterina
    Scardapane, Arnaldo
    Frediani, Bruno
    Cazzato, Massimiliano
    Salvarani, Carlo
    Iannone, Florenzo
    Manfredi, Andreina
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (22)
  • [25] Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study
    Manfredi, Andreina
    Cassone, Giulia
    Furini, Federica
    Gremese, Elisa
    Venerito, Vincenzo
    Atzeni, Fabiola
    Arrigoni, Eugenio
    Della Casa, Giovanni
    Cerri, Stefania
    Govoni, Marcello
    Petricca, Luca
    Iannone, Florenzo
    Salvarani, Carlo
    Sebastiani, Marco
    INTERNAL MEDICINE JOURNAL, 2020, 50 (09) : 1085 - 1090
  • [26] INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT
    Serrano-Combarro, A.
    Atienza-Mateo, B.
    Del-Val, N.
    Ibarrola Paino, L.
    Casafont-Sole, I.
    Melero, R.
    Perez Linaza, A.
    Serrano-Garcia, I.
    Castaneda, S.
    Ortega Castro, R.
    Calvo Gutierrez, J.
    Mena-Vazquez, N.
    Vegas-Revenga, N.
    Dominguez Casas, L.
    Delgado-Beltran, C.
    Diez, C.
    Perez Sandoval, T.
    Retuerto-Guerrero, M.
    Perez Albaladejo, L.
    Lopez-Sanchez, R.
    Mazano, M. G.
    Brandy-Garcia, A.
    Lopez Viejo, P.
    Bonilla, G.
    Maiz, O.
    Carrasco Cubero, M. D. C.
    Garijo Bufort, M.
    Moreno, M.
    Urruticoechea-Arana, A.
    Ordonez, S.
    Gonzalez-Montagut Gomez, C.
    Peralta-Gines, C.
    Osorio, M. C.
    Canadillas, E.
    De Dios Jimenez de Aberasturi, J. R.
    Lozano Morillo, F.
    Vazquez Rodriguez, T.
    Carreira, P.
    Blanco, J. M.
    Fernandez-Diaz, C.
    Loricera, J.
    Ferraz-Amaro, I.
    Ferrer, D.
    Blanco, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 225 - 227
  • [27] Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
    Fernandez-Diaz, Carlos
    Castaneda, Santos
    Ojeda-Garcia, Clara
    Olive, Alejandro
    Carreira, Patricia
    Perez Sandoval, Trinidad
    Retuerto Guerrero, Miriam
    Cervantes Perez, Evelin Cecilia
    Rodriguez, Samantha
    Robles Flores, Bryan Josue
    Hernandez-Cruz, Blanca
    Urruticoechea-Arana, Ana
    Maiz, Olga
    Palma, Desiree
    Arboleya, Luis
    Bonilla, Gema
    Rodriguez-Gomez, Manuel
    Delgado, Concepcion
    Exposito, Rosa
    Ruibal Escribano, Ana
    Blanco Madrigal, Juan
    Antonio Bernal, Jose
    Vela, Paloma
    Alvarez-Rodriguez, Belen
    Fito Manteca, Maria Concepcion
    Narvaez, Javier
    Jose Moreno, Manuel
    Lopez-Corbeto, Mireia
    Mena-Vazquez, Natalia
    Romero-Yuste, S.
    Aguilera-Cros, Clara
    Ordonez, Sergi
    Villa-Blanco, Ignacio
    Vegas-Revenga, Nuria
    Mora-Cuesta, Victor
    Loricera, Javier
    Angel Gonzalez-Gay, Miguel
    Luis Hernandez, Jose
    Blanco, Ricardo
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [28] Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept
    Mochizuki, Takeshi
    Ikari, Katsunori
    Yano, Koichiro
    Sato, Motoaki
    Okazaki, Ken
    MODERN RHEUMATOLOGY, 2019, 29 (03) : 413 - 417
  • [29] A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
    Tardella, Marika
    Di Carlo, Marco
    Carotti, Marina
    Ceccarelli, Luca
    Giovagnoni, Andrea
    Salaffi, Fausto
    INFLAMMOPHARMACOLOGY, 2022, 30 (03) : 705 - 712
  • [30] A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease
    Marika Tardella
    Marco Di Carlo
    Marina Carotti
    Luca Ceccarelli
    Andrea Giovagnoni
    Fausto Salaffi
    Inflammopharmacology, 2022, 30 : 705 - 712